|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These data implicate CCND3 as a dominant oncogene in the pathogenesis and transformation in several histologic subtypes of mature B-cell malignancies with t(6;14)(p21.1;q32.3) and suggest that CCND3 overexpression seen in about 10% of DLBCL cases may have a genetic basis.
|
11675358 |
2001 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cyclin D3 IR was positively associated with p27 IR (P =.004) but not with Ki-67 LI or tumor malignant potential.
|
13679452 |
2003 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.
|
21555162 |
2011 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We found that Wee1 expression increased in the direction of malignancy, and showed a strong, positive correlation with known biomarkers involved in cell cycle regulation: Cyclin A (p<0.0001), Ki67 (p<0.0001), Cyclin D3 (p = 0.001), p21(Cip1/WAF1) (p = 0.003), p53 (p = 0.025).
|
22719872 |
2012 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis.
|
31198407 |
2019 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Genomic changes disrupting the expression of cyclin D3 are associated with aberrant growth of several human B-lymphoid malignancies.
|
20107311 |
2010 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This dataset reveals 20 genes that are specifically mutated in either p19(ARF)-deficient, p53-deficient or wild-type mice (including Flt3, mmu-mir-106a-363, Smg6, and Ccnd3), as well as networks of significant collaborative and mutually exclusive interactions between cancer genes.
|
18485879 |
2008 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Although it is known that t(6;14)(p21;q32) induces aberrant overexpression of CCND3 in B-cell malignancies, we were able to show that CCND3, which encodes the cyclin D family member protein that controls the G1-S phase of cell cycle regulation, can also be a target of genomic gain/amplification.
|
16322284 |
2005 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although cyclin D3 was ubiquitously expressed, its expression was reduced in lymphoid malignancies with cyclin D1 or D2 overexpression.
|
10482983 |
1999 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In pulmonary carcinomas, distinct expression of the cyclin D3 protein is unlikely to be implicated in tumorigenesis, because of its expression in only a small fraction of cancer cells.It may relate to cancer progression.
|
8688970 |
1996 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cyclin D3 overexpression was noted the earliest in pancreatic intraepithelial neoplasia-1A and was prevalent in 90% to 100% of high-grade pancreatic intraepithelial neoplasias and ductal cancer.
|
15475449 |
2004 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D3 (CCND3) and CDK6 are highly expressed in T-ALL and have been effectively targeted in mutant NOTCH1-driven mouse models of this disease with a CDK4/6 small-molecule inhibitor.
|
28151717 |
2017 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma.
|
17300668 |
2007 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
While cyclin D3 expression contributes to cell-cycle progression in Notch-dependent human T-ALL cell lines, ectopic expression of CDK4 or CDK6 together with cyclin D3 shows partial rescue from gamma-secretase inhibitor (GSI)-induced G(1) arrest in these cell lines.
|
19001083 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, miR-138 is a tumor suppressor miRNA underexpressed in CML. miR-138 represses expression of both BCR-ABL and CCND3 via binding to the coding region and 3'-UTR, respectively. miR-138 expression is activated by GATA1, which in turn is repressed by BCR-ABL.
|
23208504 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the 133 cases analyzed for both cyclin D1 and cyclin D3, patients with cyclin D1+/cyclin D3+ tumors experienced the worst prognosis, patients with cyclin D1-/cyclin D3- exhibited the most prolonged survival, and with cyclin D1-/cyclin D3+ or cyclin D1+/cyclin D3- tumors an intermediate course was associated.
|
15671552 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An abnormal expression of cyclin D3, a key regulator of the cell cycle, has been documented in a variety of human malignancies, and the cyclin D3 gene, mapping to 6p21, may be deregulated in human tumors as a result of the t(6;14)(p21.1;q32.3) translocation or gene amplification.
|
13679452 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Concurrently, global transcriptional profiling analysis reveals that multiple tumor-associated genes such as CCND3, E2F1/2, HOXA1, Bcl2 modifying factor (BMF), Met, and Myc; and signaling pathways of cellular dedifferentiation, proliferation, adhesion, survival including p53, cadherin, Myc, and anti-apoptotic pathways are differentially expressed or significantly altered in these lung epithelial cells upon downregulation of H2Bub1.
|
28481029 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cyclin D3 overexpression was noted the earliest in pancreatic intraepithelial neoplasia-1A and was prevalent in 90% to 100% of high-grade pancreatic intraepithelial neoplasias and ductal cancer.
|
15475449 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patient's overall survival was associated to Cyclin D3 (p<0.0001), p53 (p=0.0017), p21Waf1 (p=0.0142), Cyclin D1 (p<0.0001), ki67-MIB1 (p=0.0450), and tumor size (p=0.0296).
|
15082203 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, it was essential to interrogate cyclin D3 function in this tumor type.
|
18084330 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Apart from chromosome content, the two pathways are distinguished by five primary immunoglobulin heavy chain (IGH) rearrangements (4p16, FGFR3, and MMSET; 6p21, CCND3; 11q13, CCND1; 16q23, MAF; 20q12, MAFB) that are present mainly in NHRD tumors.
|
18381641 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma.
|
25300797 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
While the cyclin D1 and D3 genes (CCND1 and CCND3) are recurrently involved in genomic rearrangements, especially in B-cell lymphoid neoplasias, no clear involvement of the cyclin D2 gene (CCND2) has been reported to date.
|
16270038 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that the frequently downregulated miR-138 can regulate CCND3 and function as a tumor suppressor in HCC.
|
22362728 |
2012 |